update with comment from FDA

US FDA criticizes Indian drug firm USV for problems at multiple sites

By Gareth Macdonald

- Last updated on GMT


Related tags Warning letter Pharmaceutical drug

The US FDA has called on Indian drug firm USV Private Limited to rethink how its tests for microbial contamination at its manufacturing facilities.

The US regulator said USV’s “oversight and control over the manufacture of drugs is inadequate​” in a warning letter published today, citing problems with testing procedures observed during an inspection at its plant in Dabhel, Daman in 2016.

The agency also referenced similar problems uncovered at a facility in Govandi, Mumbai in 2014​.

The Food and Drug Administration (FDA) wrote that: “These repeated problems at multiple sites demonstrate that your company’s oversight and control over the manufacture of drugs is inadequate.

You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems and processes, and ultimately, the products manufactured, conform to FDA requirements​.”

Multi-site warning letters 

The letter to USV is similar to a warning​ sent to fellow Indian drug manufacturer Wockhardt this month in which the US agency detailed problems observed at seven of the firm’s facilities in recent years. 

The FDA told us: "The USV warning letter is for a single facility, as is the Wockhardt warning letter. They each reference recently issued WL(s) to sister facilities. Though we have issued WLs to multiple sites.

The agency added that: "These are considered corporate warning letters. The scope of a corporate warning letter extends to organization-wide practices, rather than problems limited to an organizational​."

USV makes active pharmaceutical ingredients (APIs), small molecule drugs and biosimilar products. On a section about its API business on its website, the firm claims to have had a “presence in US and EU markets​” for two decades

It also says it supplies finished drugs to multiple markets, including the US and Europe.

The firm did not respond to a request for comment.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us